“…Hence, the recent revival of peptide‐based drugs both in academia and in the pharmaceutical industry comes with no surprise, as peptide therapeutics can address many unmet medical needs, by complementing or even replacing small molecules or large protein‐based therapeutics currently in the clinics (Craik, Fairlie, Liros, & Price, ; Henninot, Collins, & Nuss, ; Otvos Jr. & Wade, ). Accordingly, peptide drug sales have been steadily increasing, at present having an expected volume of sales likely over US$ 70 billion in 2019 (insulins included) (Henninot et al, ), and US$ 47 billion (insulins excluded) by 2024 (Al Musaimi, Al Shaer, de la Torre, & Albericio, ).…”